Clinical Trials
28 trialsALCG-01
Gazi University
NeoLATC
Fujian Medical University
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
University of Pittsburgh
International Multicentric Study ARON-1
Hospital of Macerata
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
University of Pittsburgh
SURROGATE-ICI
Institut Bergonié
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Asan Medical Center
APiTOXMM
University Hospital, Montpellier
Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer
Mayo Clinic
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
Fujian Medical University
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TREATMENT
Oslo University Hospital
I-STOP
University of Milano Bicocca
ST-ICI
University of Erlangen-Nürnberg Medical School
Microbiome Immunotherapy Toxicity and Response Evaluation
Cambridge University Hospitals NHS Foundation Trust
QUASAR
University of California, San Diego
Immunotherapy in Lung Cancer: Treatment After IO Cessation.
European Lung Cancer Working Party
Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer
Peking Union Medical College Hospital
A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients
Yonsei University
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Sungkyunkwan University
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
Guangdong Association of Clinical Trials
NIVEAL
University Hospital, Tours
NIVEX
Spanish Lung Cancer Group
Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Attikon Hospital